PMID: 18057338
Peptide Research
Tesamorelin
SKU: TSM10
Tesamorelin is a 44-amino-acid stabilized analog of GHRH with a trans-3-hexenoic acid modification that resists DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile GH release, which in turn elevates hepatic IGF-1. Clinical trials …
View Catalog →For Research Use Only
Mechanism of Action
Tesamorelin is a 44-amino-acid stabilized analog of GHRH with a trans-3-hexenoic acid modification that resists DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile GH release, which in turn elevates hepatic IGF-1. Clinical trials demonstrated preferential reduction of visceral adipose tissue (approximately 15-20% VAT reduction over 26 weeks) with minimal effect on subcutaneous fat. FDA-approved for HIV-associated lipodystrophy.
Research Studies
3 peer-reviewed studies curated for Tesamorelin.
Other — 3
PMID: 20554713
Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010
View on PubMed →PMID: 31237318
Adrian S et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019
View on PubMed →Related Research
Compared with CJC-1295 + Ipamorelin in GH-axis research (Tesamorelin targets VAT preferentially; CJC-1295/Ipamorelin broader GH pulsatility). Frequently paired with GLP2-TZ or GLP3-RT in body composition research. Complementary to IGF-1 LR3 for downstream growth factor studies.